Explore / Peer-reviewed article
Peer-reviewed articleOpen access

Therapeutic potential of serotoninergic psychedelic substances in the treatment of Obsessive Compulsive Disorder

Rodrigues J, Nombora O, Ribeiro L

European psychiatry : the journal of the Association of European PsychiatristsSep 1, 2022License: open access0 citations

Abstract

<h4>Introduction</h4> Obsessive Compulsive Disorder (OCD) is a psychiatric disorder associated with suffering and disability. The serotoninergic system is implicated in the neurobiological processes of OCD and serotonin reuptake inhibitors (SRIs) are the first-line treatment. However, clinical improvement after starting SRIs can take long and patients may not fully recover. Meanwhile, recent data suggests that activation of 5-HT receptors may exert a therapeutic action in obsessional symptoms. Some psychedelics are strong 5-HT2 receptor agonists and there is a growing research interest as they can be a promising therapeutic approach to OCD. <h4>Objectives</h4> We aim to provide an overview on the current evidence on the therapeutic potential of serotoninergic psychoactive substances in the treatment of OCD. <h4>Methods</h4> Non-systematic review. Literature search in the PubMed database using the terms psychedelics and obsessive-compulsive disorder. <h4>Results</h4> Although research is currently limited to a few small studies, the ones conducted so far showed clinically meaningful acute reduction of OCD symptoms after treatment with serotoninergic psychoactive drugs, as well as possible longer-lasting benefits, particularly with psilocybin and lysergic acid diethylamide (LSD). Furthermore, substance-assisted psychotherapy with psychedelics has been showing promising results, being suitable for OCD treatment. It is important to add that, to date, studies have indicated relatively good tolerability to these drugs. <h4>Conclusions</h4> These promising early findings highlight the role of psychedelics in OCD treatment and the need for further research into efficacy, therapeutic mechanisms and safety, in order to determine whether these drugs may be worthy options for OCD treatment in the future. <h4>Disclosure</h4> No significant relationships.

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

PsilocybinLSDOCD

Keywords

Obsessive Compulsive Disorder5-Ht2 Receptor AgonismSerotoninergic Psychedelics

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.